EE9900461A - Modifitseeritud TNFa molekulid, neid kodeeriv DNA ning selliseid TNFa molekule ja DNA sisaldavad vaktsiinid - Google Patents

Modifitseeritud TNFa molekulid, neid kodeeriv DNA ning selliseid TNFa molekule ja DNA sisaldavad vaktsiinid

Info

Publication number
EE9900461A
EE9900461A EEP199900461A EEP9900461A EE9900461A EE 9900461 A EE9900461 A EE 9900461A EE P199900461 A EEP199900461 A EE P199900461A EE P9900461 A EEP9900461 A EE P9900461A EE 9900461 A EE9900461 A EE 9900461A
Authority
EE
Estonia
Prior art keywords
dna
tnfα molecules
vaccines containing
modified
molecules
Prior art date
Application number
EEP199900461A
Other languages
English (en)
Estonian (et)
Inventor
Roland Jensen Martin
Mouritsen S�ren
Elsner Henrik
Dalum Iben
Original Assignee
Farmaceutisk Laboratorium Ferring A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmaceutisk Laboratorium Ferring A/S filed Critical Farmaceutisk Laboratorium Ferring A/S
Publication of EE9900461A publication Critical patent/EE9900461A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EEP199900461A 1997-04-15 1998-04-15 Modifitseeritud TNFa molekulid, neid kodeeriv DNA ning selliseid TNFa molekule ja DNA sisaldavad vaktsiinid EE9900461A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK41897 1997-04-15
US4418797P 1997-04-24 1997-04-24
PCT/DK1998/000157 WO1998046642A1 (en) 1997-04-15 1998-04-15 MODIFIED TNFα MOLECULES, DNA ENCODING SUCH MODIFIED TNFα MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFα MOLECULES AND DNA

Publications (1)

Publication Number Publication Date
EE9900461A true EE9900461A (et) 2000-06-15

Family

ID=8093298

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900461A EE9900461A (et) 1997-04-15 1998-04-15 Modifitseeritud TNFa molekulid, neid kodeeriv DNA ning selliseid TNFa molekule ja DNA sisaldavad vaktsiinid

Country Status (30)

Country Link
US (1) US7118750B1 (zh)
EP (1) EP0975668B1 (zh)
JP (1) JP2001521386A (zh)
KR (1) KR100522289B1 (zh)
CN (1) CN1178955C (zh)
AR (1) AR012427A1 (zh)
AT (1) ATE326481T1 (zh)
AU (1) AU743400B2 (zh)
BR (1) BR9811462A (zh)
CA (1) CA2289476A1 (zh)
CZ (1) CZ9903657A3 (zh)
DE (1) DE69834556T2 (zh)
DK (1) DK0975668T3 (zh)
EE (1) EE9900461A (zh)
ES (1) ES2264569T3 (zh)
HK (1) HK1022918A1 (zh)
HR (1) HRP980203B1 (zh)
HU (1) HUP0001930A3 (zh)
IL (1) IL132281A0 (zh)
NO (1) NO995002L (zh)
NZ (1) NZ337955A (zh)
PL (1) PL194221B1 (zh)
RU (1) RU2241715C2 (zh)
SI (1) SI0975668T1 (zh)
SK (1) SK285639B6 (zh)
TR (1) TR199902562T2 (zh)
TW (1) TW510921B (zh)
UA (1) UA72440C2 (zh)
WO (1) WO1998046642A1 (zh)
ZA (1) ZA983148B (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
ATE488250T1 (de) * 1999-03-02 2010-12-15 Centocor Inc Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
EE200200025A (et) 1999-07-20 2003-04-15 Pharmexa A/S Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
JP2003535905A (ja) * 2000-06-21 2003-12-02 フェリング ベスローテン フェンノートシャップ 可溶化されたタンパク質ワクチン
EP1485122A2 (en) * 2002-03-11 2004-12-15 Pharmexa A/S Novel application of vaccination against tnf-alpha
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
BRPI0407058A (pt) * 2003-02-01 2006-01-17 Neuralab Ltd Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento
CN1960744A (zh) 2004-02-27 2007-05-09 瓦克斯咨询公司 肽IL1β和TNFα以及应用其治疗的方法
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
MX2010003114A (es) * 2007-09-25 2010-06-23 Intervet Int Bv Vacuna para tratamiento de osteoartritis.
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
BR112012010698A2 (pt) 2009-11-05 2016-11-29 Uab Research Foundation método para tratamento de um sujeito com câncer, método de triagem de uma célula de câncer de mama, e , anticorpo
WO2011116344A2 (en) 2010-03-18 2011-09-22 The Uab Research Foundation Targeting cancer stem cells
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012076668A1 (en) 2010-12-08 2012-06-14 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
JP2011201902A (ja) * 2011-05-19 2011-10-13 Wyeth Llc 可溶性Ａ−βに対する抗体を生成させるための能動免疫
CN103376327A (zh) * 2012-04-28 2013-10-30 通用电气公司 检测抗体或融合蛋白的浓度的方法
AU2016256876B2 (en) 2015-05-05 2021-02-04 Rubicon Biotechnology Llc Cancer immunotherapeutic
CN106279403B (zh) * 2016-08-16 2019-06-11 长春市海兰深生物医学技术有限公司 一种检测天然肺癌相关抗体的组合物、试剂盒和方法
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE107362T1 (de) * 1986-06-20 1994-07-15 Dainippon Pharmaceutical Co Polypeptid-mutanten des menschlichen tnf und für diese mutanten codierende dns.
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU634379B2 (en) 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden

Also Published As

Publication number Publication date
NO995002L (no) 1999-12-15
TW510921B (en) 2002-11-21
TR199902562T2 (xx) 2000-02-21
IL132281A0 (en) 2001-03-19
RU2241715C2 (ru) 2004-12-10
KR100522289B1 (ko) 2005-10-19
EP0975668B1 (en) 2006-05-17
WO1998046642A1 (en) 1998-10-22
PL194221B1 (pl) 2007-05-31
HUP0001930A3 (en) 2001-10-29
US7118750B1 (en) 2006-10-10
HRP980203B1 (en) 2003-04-30
AU7030398A (en) 1998-11-11
UA72440C2 (en) 2005-03-15
CA2289476A1 (en) 1998-10-22
CN1252809A (zh) 2000-05-10
ZA983148B (en) 1999-10-15
DE69834556T2 (de) 2007-05-10
CZ9903657A3 (cs) 2001-09-12
CN1178955C (zh) 2004-12-08
SK285639B6 (sk) 2007-05-03
NZ337955A (en) 2000-09-29
NO995002D0 (no) 1999-10-14
DE69834556D1 (de) 2006-06-22
PL336295A1 (en) 2000-06-19
JP2001521386A (ja) 2001-11-06
KR20010006416A (ko) 2001-01-26
HUP0001930A2 (hu) 2000-09-28
ES2264569T3 (es) 2007-01-01
DK0975668T3 (da) 2006-09-25
EP0975668A1 (en) 2000-02-02
ATE326481T1 (de) 2006-06-15
SI0975668T1 (sl) 2007-02-28
AR012427A1 (es) 2000-10-18
AU743400B2 (en) 2002-01-24
SK140999A3 (en) 2000-06-12
BR9811462A (pt) 2000-09-12
HRP980203A2 (en) 1998-12-31
HK1022918A1 (en) 2000-08-25

Similar Documents

Publication Publication Date Title
EE9900461A (et) Modifitseeritud TNFa molekulid, neid kodeeriv DNA ning selliseid TNFa molekule ja DNA sisaldavad vaktsiinid
DE69533634D1 (de) Geranylgeranyldiphosphate-Synthase und diese kodierende DNA
ATE285767T1 (de) Kombinationstherapie, enthaltend atorvastatin und bluddrucksenkendes mittel
EE9900357A (et) Geenisekvenaator ja meetodid
EP0964930A4 (en) CATALYTIC RNA MOLECULES
DE69822473D1 (de) Lipid-polyamid-konjugate und zusammensetzungen zur verabreichung von nucleinsäuremolekülen
FR2776928B1 (fr) Vaccins adn adjuves
FI971203A (fi) Tyyppiä 6A olevaa ihmisen papillomavirusta koodaava DNA
EP1001964A4 (en) TANGO-78, TANGO-79 AND TANGO-81 NUCLEIC ACID MOLECULES
AU5874798A (en) Vaccination methods and molecules
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
ID20514A (id) Bejana metalurgi yang ditingkatkan dan metode penggunaan bejana tersebut
HUP0103784A2 (hu) MUC-1-et kódoló DNS molekulák és ezek alkalmazása tumorellenes vakcinálásban
IL138216A0 (en) Novel fdrg protein and nucleic acid molecules and uses therefor
AU5553699A (en) Dna encoding canine von willebrand factor and methods of use
EP1071749A4 (en) NUCLEIC ACID AND LRSG PROTEIN MOLECULES AND USES THEREOF
DE69532881D1 (de) Ecdn - protein und dafuer kodeierende dna
EP1044216A4 (en) DNA MOLECULES ENCODING HUMAN NUCLEAR RECEPTOR PROTEINS, nNR7 AND nNR7-1
EP1007682A4 (en) INNOVATIVE NUCLEIC ACID MOLECULES AND THEIR USE
DE69833068D1 (de) Druckverfahren und Druckmedium
EP1066310A4 (en) NEOKIN PROTEINS AND NUCLEIC ACIDS AND THEIR USE
IL124567A0 (en) Hemorrhagic enteritis virus dna sequences proteins encoded thereby and various uses thereof
GB9716641D0 (en) Vaccination methods and molecules
FR2756166B1 (fr) Rechauffe-cognac
GB9724584D0 (en) Nucleic acid vaccine molecules

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner